Dr. Abid Hamid Dar

Cancer Pharmacology Division
CSIR - Indian Institute of Integrative Medicine,Canal Road, Jammu – 180001
Email: ahdar@iiim.ac.in, abidhamid76@gmail.com

Positions Held  
Position Held Date Organization
Sr. Scientist 2012 - Present CSIR-IIIM
Honours & Awards  
  • Awarded Indo-US Research Fellowship by Indo-US, S & T Forum in 2012.

  • Awarded BOYSCAST Fellowship for Research in USA by DST, India in 2011.

  • Awarded Young Scientist Award from State, Science & Technology for 2012.

  • Awarded DST Fast Track Grant for Young Scientists in 2011.

  • Awarded AACR-2015 Travel Grant Award (Biotechne).

  • Qualified CSIR-UGC (NET)-JRF & GATE-JRF national examinations.

  • Internationally 1021 citations to the published work till date.

Research Area

  • Cancer Epigenetics & Novel Therapeutic Targets

  • Cancer Cell Signaling & Target Based Inhibitors for Drug Discovery

  • Stem Cell Biology, Epigenetics & Tissue Recombination Models in Cancer

  • Molecular Membrane Biochemistry & Cellular Biology

  • Nutrigenomics and Cancer

Few Significant Research Contributions:

  • Pathobiology & diagnostic epigenetic evaluation of human stem cells for embryonic development and placental disorders.   

  • Reported PTEN regulates polycomb repressive EZH2 expression and its deficiency correlates with active transcription mark H3K4Me3 in prostate cancer models.

  • Therapy induced catalytic EZH2 limits therapeutic responses in PTEN null prostate cancer.

  • Evaluated that YB-1 an oncogenic transcription factor regulates macrophage polarization and tumor microenvironment during carcinogenesis.

  • Discovered that Grb-10, a tumor suppressor candidate is epigenetically silenced in PTEN null tumors.

  • Designed, executed & developed the epigenetic & ageing model for liver cancer development.

  • Developed an in vivo model of aberrant one carbon metabolism and evaluated its molecular basis in genomic instability via DNA methylation.

  • Reported first time the relevance of heterochromatin methylation of human genome and Prostate-Specific Membrane Antigen induction of invasive prostate cancer development.

  • Discovered PI3K/Akt/mTOR target based tumor cell death by novel natural small molecule(s) with mechanistic evaluation that has been patented and is being further explored for drug development.

  • Studied histone deacetylase inhibition in association with aberrant cellular physiology for the understanding of epigenetics of cancer chemotherapeutics at the molecular level.



  • Rahat, B.; Mahajan, A.; Bagga, R.; Hamid, A.; Kaur, J. Epigenetic modifications at DMRs of placental genes are subjected to variations in normal gestation, pathological conditions and folate supplementation. Sci Rep. 2017 Jan 18;7:40774.
  • Rahat, B.; Najar, R.A.; Hamid, A.; Bagga, R.; Kaur, J. The role of aberrant methylation of trophoblastic stem cell origin inthe pathogenesis and diagnosis of placental disorders. Prenat Diagn. 2016 Nov 24. doi: 10.1002/pd.4974.
  • Dar, N.J.; Bhat, J.A.; Satti, N.K.; Sharma, P.R.; Hamid, A.; Ahmad, M. Withanone, an Active Constituent from Withania somnifera, Affords Protection Against NMDA-Induced Excitotoxicity in Neuron-Like Cells. Mol Neurobiol. 2016 Aug 19. [Epub ahead of print] PubMed PMID: 27541286.
  • Rahat, B.; Thakur, S.; Hamid, A.; Bagga, R.; Kaur, J. Association of aberrant methylation at promoter regions of tumor suppressor genes with placental pathologies. Epigenomics. 2016 Jun;8(6):767-87.
  • Rahat, B.; Sharma, R.; Bagga, R.; Hamid, A.; Kaur, J. Imbalance between matrix metalloproteinases and their tissue inhibitors in preeclampsia and gestational trophoblastic diseases. Reproduction. 2016 Jul;152(1):11-22.
  • Ahmad, Najar R.; Rahat, B.; Hussain, A.; Thakur, S.; Kaur, J.; Kaur, J.; Hamid, A. Gene specific epigenetic regulation of hepatic folate transport system is responsible for perturbed cellular folate status during aging and exogenous modulation. Mol Nutr Food Res. 2016 Jun;60(6):1501-13.
  • Hussain, A.; Qazi, A.K.; Mupparapu, N.; Guru, S.K.; Kumar, A.; Sharma, P.R.; Singh, S.K.; Singh, P.; Dar, M.J.; Bharate, S.B.; Zargar, M.A.; Ahmed, Q.N.; Bhushan, S.; Vishwakarma, R.A.; Hamid, A. Modulation of glycolysis and lipogenesis by novel PI3K selective molecule represses tumor angiogenesis and decreases colorectal cancer growth. Cancer Lett. 2016 May 1;374(2):250-60.
  • Hussain, A.; Qazi, A.K.; Mupparapu, N.; Kumar, A.; Mintoo, M.J.; Mahajan, G.; Sharma, P.R.; Singh, S.K.; Bharate, S.B.; Zargar, M.A.; Ahmed, Q.N.; Mondhe, D.M.; Vishwakarma, R.A.; Hamid, A. A novel PI3K axis selective molecule exhibits potent tumor inhibition in colorectal carcinogenesis. Mol Carcinog. 2016 Dec;55(12):2135-2155.
  • Lone, A.M.; Dar, N.J.; Hamid, A.; Shah, W.A.; Ahmad, M.; Bhat, B.A.; Promise of Retinoic Acid-Triazolyl Derivatives in Promoting Differentiation of Neuroblastoma Cells. ACS Chem Neurosci. 2016 Jan 20;7(1):82-9.
  • Dar, N.J.; Hamid, A.; Ahmad, M. Pharmacologic overview of Withania somnifera, the Indian Ginseng. Cell Mol Life Sci. 2015 Dec;72(23):4445-60.
  • Thakur, S.; Rahat, B.; Hamid, A.; Najar, R.A.; Kaur, J. Identification of regulatory mechanisms of intestinal folate transport in condition of folate deficiency. J Nutr Biochem. 2015 Oct;26(10):1084-94.
  • Majeed, R.; Hussain, A.; Sangwan, P.L.; Chinthakindi, P.K.; Khan, I.; Sharma, P.R.; Koul, S.; Saxena, A.K.; Hamid, A. PI3K target based novel cyano derivative of betulinic acid induces its signalling inhibition by down-regulation of pGSK3β and cyclin D1 and potentially checks cancer cell proliferation. Mol Carcinog. 2016 May;55(5):964-76.
  • Rahat, B.; Hamid, A.; Ahmad, Najar R.; Bagga, R.; Kaur, J. Epigenetic mechanisms regulate placental c-myc and hTERT in normal and pathological pregnancies; c-myc as a novel fetal DNA epigenetic marker for pre-eclampsia. Mol Hum Reprod. 2014 Oct;20(10):1026-40.
  • Dhar, N.; Rana, S.; Razdan, S.; Bhat, W.W.; Hussain, A.; Dhar, R.S.; Vaishnavi, S.; Hamid, A.; Vishwakarma, R.; Lattoo, SK. Cloning and functional characterization of three branch point oxidosqualene cyclases from Withania somnifera (L.) dunal. J Biol Chem. 2014 Jun 13;289(24):17249-67.
  • Qazi, A.K.; Hussain, A.; Khan, S.; Aga, M.A.; Behl, A.; Ali, S.; Singh, S.K.; Taneja, S.C.; Shah, B.A.; Saxena, A.K.; Mondhe, D.M.; Hamid, A. Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer. Cancer Lett. 2015 Apr 1;359(1):47-56.
  • Majeed, R.; Sangwan, P.L.; Chinthakindi, P.K.; Koul, S.; Rayees, S.; Singh, G.; Mondhe, D.M.; Mintoo, M.J.; Singh, S.K.; Rath, S.K.; Saxena, A.K.; Hamid, A. Inhibition of phosphotidylinositol-3 kinase pathway by a novel naphthol derivative of betulinic acidinduces cell cycle arrest and apoptosis in cancer cells of different origin. Cell Death Dis. 2014 Oct 9;5:e1459.


  • A Kamal, YVV Srikanth, MNA Khan, M Ashraf, I Sehar, G Chashoo, PR Sharma, AH Dar, S Bhushan, SK Singh, Mondhe DM, Saxena AK. 2-Anilino nicotinyl linked 2-amino benzothiazole conjugates as potential anticancer agents, apoptosis inducers and process for the preparation thereof. International Application No: PCT/IN2011/000217 dated Mar 30, 2011; Indian Patent Application No: 373/DEL/2011 dated Feb. 14, 2011. WO Patent No. WO2012111016 A8 and Publication date: 01.08.2013.
  • RA Vishwakarma, SD Sawant, PP Singh, AH Dar, PR Sharma, AK Saxena, A Nargotra, KA Arvind, M Ramesh, AK Qazi, A Hussain, C Nuyan. Synthesis and biological evaluation of isoform selective analogs of liphagane scaffolds as anticancer agents: PI3K-α/β inhibitors. Patent Reference No.: 195NF 2011, DEL No.: 0794DEL2012 and Filing Date: 19.03.2012. WO Patent No. WO/2013/140417 A1 and Publication date: 26.09.2013.
  • RA Vishwakarma, SK Jain, SB Bharate, AH Dar, A Khajuria, M Samdarshi, SK Bhola, AK Qazi, A Hussain, T Sidiq, R Uma Shaanker, G Ravikanth, R Vasudeva, MK Patel, KN Ganeshaiah. New chromone alkaloid dysoline for the treatment of cancer and inflammatory disorders. Patent Reference No.: 37NF 2013, DEL No.: 1077DEL2013 and Filing Date: 10.04.2013. WO Patent No. WO/2014/167580 and Publication date: 16.10.2014.
  • Vishwakarma R, Bharate SB, Kumar A, Singh B, Kumar A, Bhushan S, Hamid A, Joshi P, Guru SK, Kumar S, Hussain A, Khurshid AQ, Bharate SS, Sharma P, Saxena AK, Mondhe DM, Mahajan G, Wani Z. 10-substituted colchicinoids as potent anticancer agents. Patent Reference No.: 0059NF2014, DEL No.: 2929DEL2014  and  Filing Date: 14.10.2014. WO Patent No. WO/2016/059650 and Publication date: 21.04.2016.
  • D Singh, JP Sharma, S Jaglan, AH Dar, A Khajuria, VP Singh, Ram A Vishwakarma. Brachiatin d and process for production thereof. Patent Reference No.: 0059NF2014, DEL No.: 2563DEL2013  and  Filing Date: 30.08.2013. WO Patent No. WO2015029069 A1 and Publication date: 05.03.2015.

Recent Pass out Ph. D. Students:

S.No.    Name Present Position
Yasrib Qurishi

DBT-Postdoctoral Fellow,
Indian Institute of Science,Banglore, India.

Aashiq Hussain Postdoctoral Associate University of Alberta,
Alberta, Canada.
Rabiya Majeed

Sri Pratap College,
University of Kashmir, Srinagar.


Asif Khurshid Qazi

Postdoctoral Associate,University of Nebraska Medical Center (UNMC), Omaha, NE, USA.

Mudassier Ahmad

University of Jammu, Jammu & Kashmir, India

Present Ph.D. Students:

  • Rauf Ahmad Najar

  • Javid Ahmad Bhat

  • Nawab John Dar